BIO-Europe Spring 2019: Adrenomed’s Hein On Sepsis And Beyond
Executive Summary
Adrenomed’s chief business officer Frauke Hein explained to Mike Ward how the company has moved from establishing a diagnostic marker for septic shock to developing a therapeutic candidate.